Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Lyon, France. In Eur J Hum Genet, Feb 2016
We screened two genes, MIR146A and MIR146B, producing miR-146a and miR-146b-5p, respectively, that regulate BRCA1, and the 3'- untranslated regions (3'-UTRs) of BRCA1 and BRCA2 in the GENESIS French national case/control study (BRCA1- and BRCA2-negative breast cancer cases with at least one sister with breast cancer and matched controls).
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Houston, United States. In Ann Oncol, Feb 2016
RESULTS: Of the 1000 patients who underwent sequencing, 43 had likely pathogenic germline variants: APC (1), BRCA1 (11), BRCA2 (10), TP53 (10), MSH2 (1), MSH6 (4), PALB2 (2), PTEN (2), TSC2 (1), and RB1 (1).
Ovarian cancer treatment in mutation carriers/brcaness.
Milano, Italy. In Minerva Ginecol, Feb 2016
Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.
San Francisco, United States. In Nat Rev Cancer, Feb 2016
UNASSIGNED: Over the past 20 years, there has been considerable progress in our understanding of the biological functions of the BRCA1 and BRCA2 cancer susceptibility genes.
CDH1 germline mutations and hereditary lobular breast cancer.
Milano, Italy. In Fam Cancer, Feb 2016
UNASSIGNED: Hereditary diffuse gastric cancer is an autosomal dominant inherited disease associated of CDH1 germline mutations (that encodes for the E-cadherin protein), and lobular breast cancer is the second most frequent type of neoplasia.
ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca(2+) signaling.
More papers using
Leuven, Belgium. In Biochim Biophys Acta, Feb 2016
An important aspect of this is the identification of several major oncogenes, including Bcl-2, Bcl-XL, Mcl-1, PKB/Akt, and Ras, and tumor suppressors, such as p53, PTEN, PML, BRCA1, and Beclin 1, as direct and critical regulators of Ca(2+)-transport systems located at the ER membranes, including IP3 receptors and SERCA Ca(2+) pumps.